GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enorama Pharma AB (OSTO:ERMA) » Definitions » EV-to-EBITDA

Enorama Pharma AB (OSTO:ERMA) EV-to-EBITDA : -4.42 (As of May. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Enorama Pharma AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Enorama Pharma AB's enterprise value is kr172.72 Mil. Enorama Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was kr-39.06 Mil. Therefore, Enorama Pharma AB's EV-to-EBITDA for today is -4.42.

The historical rank and industry rank for Enorama Pharma AB's EV-to-EBITDA or its related term are showing as below:

OSTO:ERMA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -101.41   Med: -8.12   Max: -0.82
Current: -4.41

During the past 9 years, the highest EV-to-EBITDA of Enorama Pharma AB was -0.82. The lowest was -101.41. And the median was -8.12.

OSTO:ERMA's EV-to-EBITDA is ranked worse than
100% of 705 companies
in the Drug Manufacturers industry
Industry Median: 14.53 vs OSTO:ERMA: -4.41

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Enorama Pharma AB's stock price is kr2.96. Enorama Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was kr-1.956. Therefore, Enorama Pharma AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Enorama Pharma AB EV-to-EBITDA Historical Data

The historical data trend for Enorama Pharma AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enorama Pharma AB EV-to-EBITDA Chart

Enorama Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -19.16 -9.22 -8.66 -6.36 -0.86

Enorama Pharma AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.12 -0.86 -3.74 -2.96 -3.58

Competitive Comparison of Enorama Pharma AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's EV-to-EBITDA falls into.



Enorama Pharma AB EV-to-EBITDA Calculation

Enorama Pharma AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=172.723/-39.062
=-4.42

Enorama Pharma AB's current Enterprise Value is kr172.72 Mil.
Enorama Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-39.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enorama Pharma AB  (OSTO:ERMA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Enorama Pharma AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.96/-1.956
=At Loss

Enorama Pharma AB's share price for today is kr2.96.
Enorama Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.956.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Enorama Pharma AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Enorama Pharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Enorama Pharma AB (OSTO:ERMA) Business Description

Traded in Other Exchanges
N/A
Address
Sodergatan 3, Malmo, SWE, SE-211 34
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.

Enorama Pharma AB (OSTO:ERMA) Headlines

No Headlines